Reagents and methods useful for detecting diseases of the prostate, breast and ovary
CA 2304368 A1 · Owner: Gordon, Julian · Inventors: Klass, Michael R.; Granados, Edward N.; Stroupe, Stephen D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS214 and transcribed from prostate breast, or , ovary tissue, is described. These sequences are useful for the detecting diagnosing, staging, monitoring, prognosticating in vivo imaging, preventing , or treating or determining the predisposition of an individual to diseases and conditions of the prostate, breast or ovary, such as prostate, breast, or ovarian cancer. Also provided are antibodies which specifically bind to PS214encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS214 polypeptide which molecules are useful , for …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 18, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.